Neuropace, Inc. NPCE Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $99.53M-0.5% | $99.99M+5.4% | $94.86M+7.1% | $88.57M+5.1% | $84.31M+5.5% | ||
| $21.6M-5.1% | $22.77M+3.3% | $22.03M+2.5% | $21.49M+1.3% | $21.22M+1.9% | ||
| $77.93M+0.9% | $77.22M+6.0% | $72.83M+8.6% | $67.08M+6.3% | $63.08M+6.8% | ||
| 78.3%+1.1pp | 77.2%+0.5pp | 76.8%+1.0pp | 75.7%+0.9pp | 74.8%+0.9pp | ||
| $27.64M-0.9% | $27.89M+3.6% | $26.91M+3.2% | $26.09M+3.1% | $25.31M+7.0% | ||
| $47.16M+1.2% | $46.58M+2.2% | $45.6M+6.2% | $42.93M+5.6% | $40.64M+2.4% | ||
| $19.89M+4.2% | $19.09M+2.9% | $18.55M+3.4% | $17.93M+9.3% | $16.41M-5.9% | ||
| $94.69M+1.2% | $93.56M+2.8% | $91.05M+4.7% | $86.95M+5.6% | $82.36M+2.0% | ||
| -$16.76M-2.6% | -$16.34M+10.3% | -$18.22M+8.3% | -$19.87M-3.1% | -$19.27M+11.1% | ||
| -16.8%-0.5pp | -16.3%+2.9pp | -19.2%+3.2pp | -22.4%+0.4pp | -22.9%+4.3pp | ||
| $6.83M-8.5% | $7.46M-7.4% | $8.05M-6.3% | $8.59M-1.2% | $8.69M-1.2% | ||
| -$569K-17.1% | -$486K— | —— | —— | —— | ||
| -$21.57M-0.5% | -$21.47M+10.5% | -$23.99M+7.5% | -$25.94M-4.6% | -$24.81M+8.6% | ||
| -21.7%-0.2pp | -21.5%+3.8pp | -25.3%+4.0pp | -29.3%+0.1pp | -29.4%+4.5pp | ||
| -$0.65+1.5% | -$0.66+12.0% | -$0.75+9.6% | -$0.830.0% | -$0.83+11.7% | ||
| -$16.42M-2.6% | -$16.01M+10.7% | -$17.93M+8.4% | -$19.57M-3.1% | -$18.98M+11.2% | ||
| -16.5%-0.5pp | -16%+2.9pp | -18.9%+3.2pp | -22.1%+0.4pp | -22.5%+4.2pp | ||
| -$16.76M-2.6% | -$16.34M+10.3% | -$18.22M+8.3% | -$19.87M-3.1% | -$19.27M+11.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Neuropace, Inc.'s revenue?
- Neuropace, Inc. (NPCE) generated $99.5M in revenue over the trailing twelve months, up 18.1% year over year.
- Is Neuropace, Inc. profitable?
- Neuropace, Inc. is not currently profitable: it reported a net loss of $21.6M over the trailing twelve months, a -21.7% net margin.
- What are Neuropace, Inc.'s profit margins?
- Gross margin is 78.3% and operating margin is -16.8%, with a -21.7% net margin.
- What is Neuropace, Inc.'s earnings per share?
- Neuropace, Inc.'s diluted EPS over the trailing twelve months is $-0.65.
- Where does Neuropace, Inc.'s income statement data come from?
- Every line is extracted from Neuropace, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
